Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer
Status: ENROLLING_BY_INVITATION
Study type: INTERVENTIONAL
Conditions: Germline BRCA-mutated HER2-negative Breast Cancer
Interventions: DRUG: Camrelizumab+Fluzoparib
Sponsor: Peking University People's Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.